Determinants of prognosis in late chronic-phase chronic myelogenous leukemia

Journal of Clinical Oncology

Volumn 16, Issue 12, 1998, Pages 3782-3787

  Rodriguez, Jose ^a   Cortes, Jorge ^a   Smith, Terry ^a   O'Brien, Susan ^a   Rios, Mary Beth ^a   Talpaz, Moshe ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

EID: 0032423158     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.12.3782     Document Type: Article

References (23)

1. Kantarjian H, Deisseroth A, Kurzrock R, et al: Chronic myelogeneous leukemia: A concise update. Blood 82:691-703, 1993
2. Kantarjian H, Smith T, O'Brien S, et al: Prolonged survival in chronic myelogenous leukemia following cytogenetic response to alfa interferon therapy. Ann Intern Med 122:254-261, 1995
3. Sacchi S, Kantarjian HM, O'Brien S, et al: Long-term follow-up results of alfa-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. Leukemia 11:1610-1616, 1997
4. Biggs JC, Szer J, Crilley P, et al: Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 80:1352-1357, 1992
5. Thomas ED, Clift RA, Fefer A, et al: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155-163, 1986
6. Gratwohl A, Hermans J, Niederwieser D, et al: Bone marrow transplantation for chronic myeloid leukemia: Long-term results. Bone Marrow Transplant 12:509-516, 1993
7. Beelen DW, Graeven U, Elmaagacli AH, et al: Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 85:2931-2990, 1995
8. Sokal JE, Cox EB, Baccarani M, et al: Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood 63:789-799, 1984
9. Kantarjian HM, Keating MJ, Smith TL, et al: Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 88:1-8, 1990
10. Tura S, Baccarani M, Corbelli G, et al: Staging of chronic myeloid leukaemia. Br J Haematol 47:105-119, 1981
11. Zubrod CG, Schneiderman M, Frei E III, et al: Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphamide. J Chron Dis 11:7-33, 1960
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1986
13. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
14. Cox DR: Regression models and life tables. J Royal Stat Soc (B) 34:187-220, 1972
15. Grambsch PM, Therneau TM: Proportional hazard tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
16. Goldman JM, Szydlo R, Horowitz MM, et al: Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235-2238, 1993
17. Biggs JC, Szer J, Crilley P, et al: Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 80:1352-1357, 1992
18. Goldman JM, Gale RP, Horowitz MM, et al: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann Intern Med 108:806-814, 1988
19. Horowitz MM, Giralt S, Szydlo R, et al: Effect of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia in first chronic phase. Blood 88:682a, 1996 (abstr 2716)
20. Shepherd P, Richards S, Allan N: Survival after allogeneic bone marrow transplantation (BMT) in patients randomized into a trial of IFN-A versus chemotherapy: No significant adverse effect of prolonged IFN-A administration. Blood 86:94a, 1995 (abstr 363)
21. Giralt S, Kantarjian H, Talpaz M, et al: Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 11:1055-1061, 1993
22. Hehlmann R, Kolb HJ, Berger U, et al: Influence of pretransplant treatment on survival after allogenous bone marrow transplantation in CML. Blood 90:228a, 1997 (suppl 1, abstr 1005)
23. Morton AJ, Gooley T, Hansen JA, et al: Impact of pre-transplant interferon-α on outcome of unrelated donor marrow transplants for chronic myeloid leukemia in first chronic phase. Blood 90:123a, 1997 (suppl 1, abstr 536)